Stocks · Healthcare · Biotechnology
Legend Biotech Corporation LEGN
$18.77 +1.08% Close, Oct 5, 2026 · NASDAQ · Market cap $3.43B
Strong growth
Next earnings report: Nov 11, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -4.4% from -27.2% a year earlier.
- Revenue over the last four quarters was $1.27B, up 59.5% from a year earlier, accelerating from 56.4% a quarter earlier.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
Growth96Exceptional
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 14%
- Revenue growth, 3-year CAGRTop 7%
- Revenue growth accelerationTop 22%
Quality37Weak
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 36%
- Gross marginBottom 41%
- Operating marginTop 47%
- Accruals (lower is better)Bottom 10%
- Interest coverBottom 44%
Value65Positive
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 38%
- Free-cash-flow yieldBottom 43%
- EBITDA / enterprise valueTop 38%
- Sales / enterprise valueTop 31%
Momentum22Very weak
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 16%
- 6-month returnBottom 42%
- 1-year return vs S&P 500Bottom 14%
- Distance from 52-week highBottom 28%
- Trend checklist (0–4)Bottom 36%
Revisions21Very weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 47%
- Upside to consensus price targetTop 17%
Stability55Neutral
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 38%
- Maximum drawdown, 3 yearsBottom 40%
- Beta vs S&P 500 (lower is better)Top 23%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 56.4% | 59.5% | ↑ |
| Gross margin | 62.5% | 56.6% | ↓ |
| Operating margin | -27.2% | -4.4% | ↑ |
| FCF margin | -36.4% | -20.1% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 59.5% | 56.4% | ↑ | Top 14% |
| Gross margin | 56.6% | 62.5% | ↓ | Bottom 41% |
| Operating margin | -4.4% | -27.2% | ↑ | Top 47% |
| Net margin | -7.2% | -40.8% | ↑ | — |
| Free-cash-flow margin | -20.1% | -36.4% | ↑ | — |
| Return on invested capital | -3.7% | — | Top 36% | |
| Revenue growth, 3-year CAGR | 106.4% | — | Top 7% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 5.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 2.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -73.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -3.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -6.22%
- Shareholder yield
- -6.22%
- Share count change, 1 year
- +5.2%
- Share count change, 3-year CAGR
- +3.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +2.4%
- Positive 20 days after report
- 2 of 8
Analysts
- Consensus price target
- $61.43
- Target vs current price
- +227.3%
- Analysts with a rating
- 20
- Share rating Buy or Strong Buy
- 75%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | -25.0% | +5.7% | -0.0% | -0.8% | — |
| May 12, 2026 | -650.0% | +10.5% | +5.5% | +30.9% | -24.6% |
| Mar 10, 2026 | +52.9% | +2.2% | -0.2% | -6.0% | +88.0% |
| Nov 12, 2025 | +15.4% | -2.7% | -8.1% | -27.1% | -46.3% |
| Aug 11, 2025 | -199.7% | -2.1% | +1.4% | -6.4% | -13.2% |
| May 13, 2025 | +69.0% | -4.0% | -10.1% | +16.2% | +15.6% |
| Mar 11, 2025 | +39.5% | +9.3% | +11.5% | -11.1% | -10.8% |
| Nov 12, 2024 | +3.5% | +0.3% | -6.5% | -5.3% | -10.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | $0.09 | $0.12 | -25.0% | $387.5M |
| May 12, 2026 | -$0.15 | -$0.02 | -650.0% | $305.1M |
| Mar 10, 2026 | -$0.08 | -$0.17 | +52.9% | $306.3M |
| Nov 12, 2025 | -$0.11 | -$0.13 | +15.4% | $272.3M |
| Aug 11, 2025 | -$0.34 | -$0.11 | -199.7% | $255.1M |
| May 13, 2025 | -$0.07 | -$0.23 | +69.0% | $195.1M |
| Mar 11, 2025 | -$0.15 | -$0.25 | +39.5% | $186.5M |
| Nov 12, 2024 | -$0.34 | -$0.35 | +3.5% | $160.2M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 2.39× | — | — | Top 31% |
| Free-cash-flow yield | -7.44% | — | — | Bottom 43% |
| Earnings yield | -2.72% | — | — | Top 38% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -12.9%
- 200-day average slope (20 days)
- -3.2%
- Distance from 50-day average
- -5.1%
- Distance from 200-day average
- -16.2%
- RSI (14)
- 45.5
- Relative volume
- 0.75×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 61.7%
- Volatility vs own 5-year history
- 79th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.64
- Correlation with S&P 500
- 0.16
- Current drawdown from 1-year high
- -48.3%
- Maximum drawdown, 3 years
- -76.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jul 28, 2023 | Feb 4, 2026 | -78.2% | 632 days | Not yet recovered |
| Oct 11, 2021 | Mar 14, 2022 | -45.6% | 106 days | 77 days (Jul 5, 2022) |
| Jul 5, 2022 | Sep 27, 2022 | -32.8% | 59 days | 75 days (Jan 13, 2023) |
| Jul 22, 2021 | Aug 19, 2021 | -28.0% | 20 days | 29 days (Sep 30, 2021) |
| Jan 19, 2021 | Mar 4, 2021 | -27.3% | 31 days | 52 days (May 18, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.43B
- EPS, diluted (TTM)
- -$0.51
- Revenue (TTM)
- $1.27B
- 52-week range
- $16.24 – $37.50
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $68.8M | $117.0M | $285.1M | $627.2M | $1.03B |
| Gross profit | $68.8M | $51.6M | $140.9M | $392.7M | $620.8M |
| Operating income | -$392.3M | -$455.6M | -$439.5M | -$303.2M | -$136.5M |
| Net income | -$403.6M | -$446.3M | -$518.3M | -$177.0M | -$296.8M |
| EPS (diluted) | -$2.74 | -$2.81 | -$2.94 | -$0.97 | -$1.60 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $160.2M | $186.5M | $195.1M | $255.1M | $272.3M | $306.4M | $305.1M | $387.5M |
| Net income | -$125.3M | $26.3M | -$100.9M | -$125.4M | -$39.7M | -$30.8M | -$54.3M | $33.2M |
| EPS (diluted) | -$0.68 | $0.14 | -$0.55 | -$0.68 | -$0.22 | -$0.17 | -$0.30 | $0.18 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$198.5M | -$201.3M | -$393.3M | -$144.0M | -$100.5M |
| Capital expenditure | -$45.4M | -$22.3M | -$22.7M | -$14.1M | -$67.6M |
| Free cash flow | -$243.9M | -$223.6M | -$416.0M | -$158.1M | -$168.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $623.4M | $377.6M | $0 | $0 | $3.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $964.6M
- Total assets
- $1.75B
- Total liabilities
- $521.3M
- Total debt
- $278.2M
- Net debt
- -$394.7M
- Shareholders’ equity
- $1.23B
As of Jun 30, 2026 (filed Aug 11, 2026).
Short interest
- Shares sold short
- 14,637,187
- Days to cover
- 7.09
- Change vs previous report
- -11.2%
FINRA short interest, settlement date Sep 15, 2026.